secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2024-02-21T23:59:59+00:00
Accession:  0001193125-24-041514
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Vanda approves 2023 bonuses, 2024 salaries, and RSU grants for NEOs
-------------------------------------------------------------------

- CEO Polymeropoulos receives $983K bonus for 2023, 450,000 RSUs vesting over 4 years.
- 2024 base salaries: CEO $933K, CFO Moran $541K, others $541-560K.
- 2024 target bonuses: 80% CEO, 45% for other NEOs.
- RSU grants total 857,700 shares across five executives.
- Compensation committee reviewed Willis Towers Watson peer group analysis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000119312524041514/0001193125-24-041514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000119312524041514/d796267d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-041514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer